Copper

證據等級: L5

預測適應症: 10 個

Copper: From No Established Indication to Esotropia

One-Sentence Summary

Copper (DB09130) is an essential trace element with no currently registered therapeutic drug indication in South Africa. The TxGNN model predicts it may be effective for Esotropia (inward ocular deviation), achieving a prediction score of 96.25%; however, there are no clinical trials and no publications currently supporting this specific indication, placing evidence at the lowest confidence level (L5).

Quick Overview

Item	Content
Original Indication	No established therapeutic indication
Predicted New Indication	Esotropia
TxGNN Prediction Score	96.25%
Evidence Level	L5
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for Copper (DB09130) is not currently available. As an essential trace element, copper serves as a cofactor for several key enzymes — including superoxide dismutase (Cu/Zn-SOD, antioxidant defence), cytochrome c oxidase (mitochondrial energy production), ceruloplasmin (iron metabolism), and lysyl oxidase (LOX/LOXL, extracellular matrix crosslinking of collagen and elastin). These broad biological roles underpin its involvement in numerous physiological processes.

The theoretical connection to esotropia is weak. Copper-dependent LOX enzymes are involved in the structural integrity of connective tissue, which includes the periorbital fascia and extraocular muscle sheaths. One could hypothesise that copper deficiency might impair connective tissue support around the eye. However, esotropia is fundamentally a neuromuscular coordination disorder — caused by refractive error, oculomotor nerve palsy, or muscle imbalance — not by connective tissue failure. Systemic copper supplementation has no recognised role in correcting ocular alignment.

The high TxGNN prediction score (96.25%) most likely reflects indirect node connections between copper and ocular disease entities within the underlying knowledge graph, rather than a direct or biologically validated therapeutic mechanism. No preclinical, animal model, or clinical study has been identified to support this prediction. This is a computational signal only, and should not be interpreted as biological plausibility.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Copper (DB09130) is not registered with SAHPRA and has no approved product licences in South Africa. It is not included on the Essential Medicines List (EML) as a standalone therapeutic agent.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical, preclinical, or mechanistic evidence supporting the use of copper as a therapeutic agent for esotropia. The TxGNN model assigns a high score, but this is almost certainly an artefact of knowledge graph topology rather than a true biological signal. With zero supporting studies (L5 evidence), this candidate does not meet the threshold to advance beyond initial screening.

To proceed, the following is needed:

Identification of a credible mechanistic hypothesis linking copper homeostasis to oculomotor or neuromuscular function in esotropia
Preclinical studies (in vitro or animal strabismus models) evaluating the effect of copper on extraocular muscle function or ocular alignment
Mechanism of action data (MOA) from DrugBank (currently a data gap)
SAHPRA registration and an approved Professional Information (PI) document to enable safety screening
Investigation of whether any copper deficiency states are associated with strabismus in the clinical literature
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.